Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
August 27, 2008

LGC Buys Fluidigm's Integrated Fluidic Circuit Technology

  • Fluidigm reports that LGC, a company focused on laboratory services and measurement standards, has purchased a BioMark™ System for genetic analysis for use in its U.K. laboratories. The system with its integrated fluidic circuit (IFC) technology adds digital PCR to LGC's existing range of capabilities, which includes quantitative PCR, genotyping, gene expression, copy number variation, and absolute quantification for sequencing.

    LGC is the first company in the U.K. to buy the system. Initial LGC work with IFC technology will focus on digital PCR and gene expression opportunities within the company's research and technology division. It will be used to look at the accurate quantification of rare target sequences for diagnostic development and for monitoring the efficiency of drugs. Further application across the company's three other divisions, LGC standards, life & food sciences, and LGC forensics, is anticipated.

    The BioMark System uses integrated fluidic circuit technology to reduce complexity, improve throughput with nanoliter precision, and provide cost-savings (less reagent and smaller samples) for high-throughput genotyping applications, according to Fluidigm.